ImmunityBio’s (IBRX) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research note released on Monday,Benzinga reports. D. Boral Capital currently has a $30.00 price target on the stock.

Separately, EF Hutton Acquisition Co. I raised ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd.

ImmunityBio Stock Down 1.8 %

IBRX stock opened at $2.76 on Monday. ImmunityBio has a 52-week low of $2.50 and a 52-week high of $10.53. The firm has a market cap of $1.92 billion, a P/E ratio of -3.00 and a beta of 0.86. The company’s 50-day simple moving average is $4.19 and its 200-day simple moving average is $4.46.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of IBRX. Victory Capital Management Inc. increased its stake in ImmunityBio by 16.0% during the 2nd quarter. Victory Capital Management Inc. now owns 19,953 shares of the company’s stock worth $126,000 after buying an additional 2,746 shares in the last quarter. Wealth Effects LLC boosted its stake in shares of ImmunityBio by 3.4% in the third quarter. Wealth Effects LLC now owns 90,500 shares of the company’s stock worth $337,000 after acquiring an additional 3,000 shares during the last quarter. Exchange Traded Concepts LLC increased its position in shares of ImmunityBio by 8.4% during the third quarter. Exchange Traded Concepts LLC now owns 47,984 shares of the company’s stock worth $178,000 after purchasing an additional 3,722 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in ImmunityBio by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after purchasing an additional 4,545 shares during the last quarter. Finally, Courier Capital LLC lifted its holdings in ImmunityBio by 50.0% in the 3rd quarter. Courier Capital LLC now owns 30,000 shares of the company’s stock valued at $112,000 after purchasing an additional 10,000 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.